FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1993609519> ?p ?o ?g. }

• W1993609519 endingPage "445" @default.
• W1993609519 startingPage "435" @default.
• W1993609519 abstract "Assess perampanel's efficacy and safety as adjunctive therapy in adolescents (ages 12-17) with drug-resistant partial seizures.Adolescent patients enrolled in multinational, double-blind, placebo-controlled, phase III core studies (studies 304, 305, or 306) completed 19-week, double-blind phase (6-week titration/13-week maintenance) with once-daily perampanel or placebo. Upon completion, patients were eligible for the extension (study 307), beginning with 16-week, blinded conversion, during which placebo patients switched to perampanel. Patients then entered the open-label treatment.Of 1480 patients from the core studies, 143 were adolescents. Pooled adolescent data from these core studies demonstrated median percent decreases in seizure frequency for perampanel 8 mg (34.8%) and 12 mg (35.6%) were approximately twice that of placebo (18.0%). Responder rates increased with perampanel 8 mg (40.9%) and 12 mg (45.0%) versus placebo (22.2%). Adolescents receiving concomitant enzyme-inducing antiepileptic drugs (AEDs) had smaller reductions in seizure frequency (8 mg:31.6%; 12 mg:26.8%) than those taking non-inducing AEDs (8 mg:54.6%; 12 mg:52.7%). Relative to pre-perampanel baseline, seizure frequency and responder rates during the extension (Weeks 1-52) improved with perampanel. Most commonly reported adverse events in adolescents during the core studies were dizziness (20.4%), somnolence (15.3%), aggression (8.2%), decreased appetite (6.1%), and rhinitis (5.1%). Dizziness (13.2%), somnolence (11.6%), and aggression (6.6%) most often led to perampanel interruption/dose adjustment during the extension.Data demonstrated adjunctive perampanel treatment in adolescents with drug-resistant partial seizures produced better seizure control versus placebo, sustained seizure frequency improvements, and a generally favorable safety profile. Results were comparable to the overall study population.clinicaltrials.gov Identifiers: Study 304: NCT00699972; 305: NCT00699582; 306: NCT00700310; Study 307: NCT00735397." @default.
• W1993609519 created "2016-06-24" @default.
• W1993609519 creator A5006329362 @default.
• W1993609519 creator A5012163356 @default.
• W1993609519 creator A5025122018 @default.
• W1993609519 creator A5035725342 @default.
• W1993609519 creator A5038032789 @default.
• W1993609519 creator A5045681106 @default.
• W1993609519 creator A5055321718 @default.
• W1993609519 creator A5063400633 @default.
• W1993609519 creator A5075327644 @default.
• W1993609519 creator A5084704668 @default.
• W1993609519 date "2015-07-01" @default.
• W1993609519 modified "2023-10-04" @default.
• W1993609519 title "Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study" @default.
• W1993609519 cites W1498758291 @default.
• W1993609519 cites W1546717111 @default.
• W1993609519 cites W1551373999 @default.
• W1993609519 cites W1584659697 @default.
• W1993609519 cites W1920696238 @default.
• W1993609519 cites W1974809694 @default.
• W1993609519 cites W1979519368 @default.
• W1993609519 cites W2008399541 @default.
• W1993609519 cites W2021767673 @default.
• W1993609519 cites W2023205599 @default.
• W1993609519 cites W2035775274 @default.
• W1993609519 cites W2045897471 @default.
• W1993609519 cites W2048095005 @default.
• W1993609519 cites W2056957815 @default.
• W1993609519 cites W2063394491 @default.
• W1993609519 cites W2069987842 @default.
• W1993609519 cites W2071065489 @default.
• W1993609519 cites W2074251342 @default.
• W1993609519 cites W2089961081 @default.
• W1993609519 cites W2106929352 @default.
• W1993609519 cites W2132687986 @default.
• W1993609519 cites W2135808877 @default.
• W1993609519 cites W2140614993 @default.
• W1993609519 cites W2145520222 @default.
• W1993609519 cites W4236676256 @default.
• W1993609519 cites W4243636870 @default.
• W1993609519 doi "https://doi.org/10.1016/j.ejpn.2015.02.008" @default.
• W1993609519 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25823975" @default.
• W1993609519 hasPublicationYear "2015" @default.
• W1993609519 type Work @default.
• W1993609519 sameAs 1993609519 @default.
• W1993609519 citedByCount "69" @default.
• W1993609519 countsByYear W19936095192015 @default.
• W1993609519 countsByYear W19936095192016 @default.
• W1993609519 countsByYear W19936095192017 @default.
• W1993609519 countsByYear W19936095192018 @default.
• W1993609519 countsByYear W19936095192019 @default.
• W1993609519 countsByYear W19936095192020 @default.
• W1993609519 countsByYear W19936095192021 @default.
• W1993609519 countsByYear W19936095192022 @default.
• W1993609519 countsByYear W19936095192023 @default.
• W1993609519 crossrefType "journal-article" @default.
• W1993609519 hasAuthorship W1993609519A5006329362 @default.
• W1993609519 hasAuthorship W1993609519A5012163356 @default.
• W1993609519 hasAuthorship W1993609519A5025122018 @default.
• W1993609519 hasAuthorship W1993609519A5035725342 @default.
• W1993609519 hasAuthorship W1993609519A5038032789 @default.
• W1993609519 hasAuthorship W1993609519A5045681106 @default.
• W1993609519 hasAuthorship W1993609519A5055321718 @default.
• W1993609519 hasAuthorship W1993609519A5063400633 @default.
• W1993609519 hasAuthorship W1993609519A5075327644 @default.
• W1993609519 hasAuthorship W1993609519A5084704668 @default.
• W1993609519 hasBestOaLocation W19936095191 @default.
• W1993609519 hasConcept C118552586 @default.
• W1993609519 hasConcept C126322002 @default.
• W1993609519 hasConcept C142724271 @default.
• W1993609519 hasConcept C15744967 @default.
• W1993609519 hasConcept C197934379 @default.
• W1993609519 hasConcept C199475168 @default.
• W1993609519 hasConcept C204787440 @default.
• W1993609519 hasConcept C27081682 @default.
• W1993609519 hasConcept C2778186239 @default.
• W1993609519 hasConcept C2779034229 @default.
• W1993609519 hasConcept C2780836401 @default.
• W1993609519 hasConcept C3018162438 @default.
• W1993609519 hasConcept C42219234 @default.
• W1993609519 hasConcept C57658597 @default.
• W1993609519 hasConcept C67761136 @default.
• W1993609519 hasConcept C71924100 @default.
• W1993609519 hasConceptScore W1993609519C118552586 @default.
• W1993609519 hasConceptScore W1993609519C126322002 @default.
• W1993609519 hasConceptScore W1993609519C142724271 @default.
• W1993609519 hasConceptScore W1993609519C15744967 @default.
• W1993609519 hasConceptScore W1993609519C197934379 @default.
• W1993609519 hasConceptScore W1993609519C199475168 @default.
• W1993609519 hasConceptScore W1993609519C204787440 @default.
• W1993609519 hasConceptScore W1993609519C27081682 @default.
• W1993609519 hasConceptScore W1993609519C2778186239 @default.
• W1993609519 hasConceptScore W1993609519C2779034229 @default.
• W1993609519 hasConceptScore W1993609519C2780836401 @default.
• W1993609519 hasConceptScore W1993609519C3018162438 @default.
• W1993609519 hasConceptScore W1993609519C42219234 @default.
• W1993609519 hasConceptScore W1993609519C57658597 @default.

• next